PCRX Cash-Secured Put Strategy

PCRX (Pacira BioSciences, Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.

PCRX (Pacira BioSciences, Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $1.46B, a trailing P/E of 38.52, a beta of 0.25 versus the broader market, a 52-week range of 18.8-36.67, average daily share volume of 1.1M, a public-listing history dating back to 2011, approximately 827 full-time employees. These structural characteristics shape how PCRX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.25 indicates PCRX has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 38.52 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.

What is a cash-secured put on PCRX?

A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.

PCRX snapshot

As of November 13, 2026, spot at $36.33. The cash-secured put on PCRX below is built from the November 13, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 63-day expiry.

Why this cash-secured put structure on PCRX specifically: IV rank is unavailable in the current snapshot, so regime-based timing for PCRX is inferred from ATM IV alone. The 63-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PCRX expiries trade a higher absolute premium for lower per-day decay. Position sizing on PCRX should anchor to the underlying notional of $36.33 per share and to the trader's directional view on PCRX stock.

PCRX cash-secured put setup

The PCRX cash-secured put below is built from the November 13, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PCRX at $36.33 on that close, the first option leg uses a $34.51 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PCRX chain at a 63-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PCRX shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Sell 1Put$34.51N/A

PCRX cash-secured put risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.

PCRX cash-secured put payoff curve

Modeled P&L at expiration across a range of underlying prices for the cash-secured put on PCRX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use cash-secured put on PCRX

Cash-secured puts on PCRX earn premium while a trader waits to acquire PCRX stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning PCRX.

PCRX thesis for this cash-secured put

A PCRX cash-secured put lets a trader earn premium while waiting to acquire PCRX at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. As a Healthcare name, PCRX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PCRX-specific events.

PCRX cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PCRX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PCRX alongside the broader basket even when PCRX-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on PCRX carry tail risk when realized volatility exceeds the implied move; review historical PCRX earnings reactions and macro stress periods before sizing. Always rebuild the position from current PCRX chain quotes before placing a trade.

Frequently asked questions

What is a cash-secured put on PCRX?
A cash-secured put on PCRX is the cash-secured put strategy applied to PCRX (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With PCRX stock at $36.33 on the November 13, 2026 close, the strikes shown on this page are snapped to the nearest listed PCRX chain strike and the premiums come straight from that session's bid/ask midpoint.
How are PCRX cash-secured put max profit and max loss calculated?
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the PCRX cash-secured put priced from the November 13, 2026 end-of-day chain at a 30-day expiry (ATM IV the current ATM IV), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a PCRX cash-secured put?
The breakeven for the PCRX cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from the November 13, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk.
When should you consider a cash-secured put on PCRX?
Cash-secured puts on PCRX earn premium while a trader waits to acquire PCRX stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning PCRX.
How does current PCRX implied volatility affect this cash-secured put?
Current PCRX ATM IV is the current ATM IV; IV rank context is unavailable in the current snapshot.

Related PCRX analysis